All In MedTech

Device Trial Radar · NCT07853196

Effects of Hyaluronic Acid Complex and Dexamethasone on Pain, Swelling, and Trismus After Mandibular Third Molar Surgery

Comparative Evaluation of the Effects of Hyaluronic Acid Complex and Dexamethasone on Postoperative Pain, Edema, and Trismus Following Mandibular Third Molar Surgery

Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

45

Actual

Start

Mar 5, 2026

Primary completion

Jul 25, 2026

Study completion Jul 25, 2026

Sponsor

Lead sponsor
Cyprus Health and Social Sciences UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 1, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aimed to comparatively evaluate the effects of a hyaluronic acid complex and dexamethasone on postoperative pain, swelling, and trismus following mandibular third molar surgery, compared with a control group. Participants were evaluated in three groups: a hyaluronic acid complex group, a dexamethasone group, and a control group. Postoperative pain, facial swelling, and limitation of mouth opening were assessed during the postoperative follow-up period to compare postoperative outcomes among the groups.

Conditions

  • Postoperative Morbidity

Interventions

  • Hyaluronic Acid ComplexDrug

    Monovisc® (Anika Therapeutics, Inc., Bedford, MA, USA), containing 22 mg/mL cross-linked, high-molecular-weight sodium hyaluronate, was used. A 0.2 mL volume of the preparation (equivalent to 4.4 mg sodium hyaluronate) was applied directly into the extraction socket using a sterile applicator. SPONGOSTAN™ Dental absorbable hemostatic gelatin sponge was subsequently placed into the socket to enhance retention of the preparation.

  • DexamethasoneDrug

    DEKORT® 8 mg/2 mL solution for I.M./I.V. injection (DEVA Holding A.Ş., Türkiye) was used. A 1.5 mL volume of the solution, corresponding to 6 mg dexamethasone, was absorbed into a SPONGOSTAN™ Dental absorbable hemostatic gelatin sponge and placed directly into the extraction socket.

  • Absorbable Hemostatic Gelatin Sponge (SPONGOSTAN™ Dental)Device

    SPONGOSTAN™ Dental absorbable hemostatic gelatin sponge (MS0005; 1 × 1 × 1 cm; Ethicon, Johnson \& Johnson) was placed directly into the extraction socket. In the control group, the gelatin sponge was used without hyaluronic acid or dexamethasone.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Postoperative Pain Assessed Using the Visual Analog Scale (VAS)Time frame: Postoperative days 1, 2, 3, and 7
  2. Facial Swelling Assessed Using Facial MeasurementsTime frame: Preoperatively and on postoperative days 1, 2, 3, and 7
  3. Trismus Assessed by Maximum Interincisal Mouth OpeningTime frame: Preoperatively and on postoperative days 1, 2, 3, and 7

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • NEW Cyprus Health and Social Sciences University

    Mórfou, Guzelyurt, Cyprus

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.